Should I buy or sell Outlook Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OTLK shares. View OTLK analyst ratings or view top-rated stocks .

What is Outlook Therapeutics' stock price target for 2024?

8 brokers have issued twelve-month target prices for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they expect the company's stock price to reach $46.43 in the next year. This suggests a possible upside of 486.2% from the stock's current price. View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts .

How have OTLK shares performed in 2024?

Outlook Therapeutics' stock was trading at $7.88 on January 1st, 2024. Since then, OTLK shares have increased by 0.5% and is now trading at $7.92. View the best growth stocks for 2024 here .

When is Outlook Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our OTLK earnings forecast .

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its quarterly earnings data on Wednesday, December, 22nd. The company reported ($1.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.60.

When did Outlook Therapeutics' stock split?

Outlook Therapeutics's stock reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB) , KushCo (KSHB) , Bionano Genomics (BNGO) , SCYNEXIS (SCYX) , ADMA Biologics (ADMA) , Zosano Pharma (ZSAN) , Novan (NOVN) , Organigram (OGI) and CNBX Pharmaceuticals (CNBX) .

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.62%), Rosalind Advisors Inc. (2.40%), BNP Paribas Financial Markets (0.03%) and American International Group Inc. (0.03%). Insiders that own company stock include C Russell Trenary III , Ghiath M Sukhtian , Jeff Evanson , Kurt J Hilzinger, Terry Dagnon and Yezan Munther Haddadin . View institutional ownership trends .

How do I buy shares of Outlook Therapeutics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OTLK

Outlook Therapeutics (OTLK) Stock Price, News & Analysis

→ Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad)

Free OTLK Stock Alerts

$8.03

+0.25 (+3.21%)

(As of 02:15 PM ET)

Compare

Today's Range: $7.68
▼
$8.05
50-Day Range: $5.73
▼
$11.94
52-Week Range: $4.00
▼
$40.60

Volume: 189,730 shs
Average Volume: 480,908 shs
Market Capitalization: $104.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.43

Outlook Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 486.2% Upside
$46.43 Price Target
Short Interest: Bearish
7.65% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.10
Based on 11 Articles This Week
Insider Trading: Acquiring Shares
$22,245 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.99) to ($1.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

Medical Sector

706th out of 918 stocks

Biological Products, Except Diagnostic Industry

117th out of 155 stocks

3.4

Analyst's Opinion

Consensus Rating
Outlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Outlook Therapeutics has only been the subject of 2 research reports in the past 90 days.
Read more about Outlook Therapeutics' stock forecast and price target.

2.0

Short Interest

Percentage of Shares Shorted
7.65% of the float of Outlook Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Outlook Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Outlook Therapeutics has recently increased by 11.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Outlook Therapeutics does not currently pay a dividend.
Dividend Growth
Outlook Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OTLK.

1.1

News and Social Media Coverage

News Sentiment
Outlook Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Outlook Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 18 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -68% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Outlook Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,245.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Outlook Therapeutics is held by insiders.
Percentage Held by Institutions
Only 11.20% of the stock of Outlook Therapeutics is held by institutions.
Read more about Outlook Therapeutics' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Outlook Therapeutics are expected to grow in the coming year, from ($2.99) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Outlook Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Outlook Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Read more about Outlook Therapeutics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Outlook Therapeutics Stock (NASDAQ:OTLK)

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OTLK Stock News Headlines

May 20 at 3:24 AM | americanbankingnews.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) to Post Q1 2025 Earnings of ($1.00) Per Share, HC Wainwright Forecasts

May 19 at 5:04 AM | americanbankingnews.com

Outlook Therapeutics (NASDAQ:OTLK) Rating Reiterated by HC Wainwright

May 17 at 4:13 PM | markets.businessinsider.com

Buy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial Position

May 17 at 11:13 AM | msn.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Call Transcript

May 17 at 11:13 AM | finance.yahoo.com

Q2 2024 Outlook Therapeutics Inc Earnings Call

May 15, 2024 | globenewswire.com

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

May 14, 2024 | americanbankingnews.com

Outlook Therapeutics (OTLK) Set to Announce Quarterly Earnings on Thursday

May 13, 2024 | globenewswire.com

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

May 9, 2024 | finance.yahoo.com

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

May 9, 2024 | globenewswire.com

Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast

May 3, 2024 | finance.yahoo.com

Global $320 Billion Aviation Fuel Market Outlook, 2024-2029: Emission Reduction Initiatives, Rising Air Freight Demand, Emerging Markets

May 3, 2024 | msn.com

How to fix Microsoft Outlook

May 2, 2024 | globenewswire.com

Outlook Therapeutics® to Present at the Retina World Congress 2024

April 29, 2024 | globenewswire.com

Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

April 29, 2024 | msn.com

These 5 programs are way better than Microsoft Outlook

April 29, 2024 | usnews.com

HCLTech Falls Most in Nearly 17 Months on Lower-Than-Expected FY25 Outlook

April 29, 2024 | finance.yahoo.com

Best's Market Segment Report: AM Best Maintains Stable Outlook on Insurance Markets of Gulf Cooperation Council

April 26, 2024 | finance.yahoo.com

Global Aluminum Wire with a Focus on Aerospace Market Outlook 2023-2036

April 26, 2024 | msn.com

How to Use Copilot in Outlook

April 22, 2024 | finance.yahoo.com

Best's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positive

April 22, 2024 | markets.businessinsider.com

WGA Releases New Housing Finance Outlook

April 22, 2024 | msn.com

Outlook: How to set up breaks between your meetings

April 21, 2024 | finance.yahoo.com

Outlook Therapeutics, Inc. (OTLK)

April 18, 2024 | finance.yahoo.com

World Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Prices

April 18, 2024 | usnews.com

Bosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024

See More Headlines

Company Calendar

Last Earnings: 12/22/2021
Today: 5/20/2024
Next Earnings (Estimated): 8/12/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:OTLK
CUSIP: N/A
CIK: 1649989
Web: www.outlooktherapeutics.com
Phone: (609) 619-3990
Fax: N/A
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $46.43
High Stock Price Target: $100.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +496.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -3,741.39%
Return on Assets: -167.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.07
Quick Ratio: 0.44

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($10.32) per share
Price / Book: -0.75

Miscellaneous

Outstanding Shares: 13,013,000
Free Float: 12,323,000
Market Cap: $101.24 million
Optionable: Optionable
Beta: 0.28

Key Executives

Mr. Ralph H. Thurman (Age 75)
Independent Executive Chairman
Comp: $207.5k
Mr. C. Russell Trenary III (Age 66)
President, CEO & Director
Comp: $610.9k
Mr. Lawrence A. Kenyon CPA (Age 58)
Executive VP, CFO, Treasurer, Company Secretary & Director
Mr. Jeffrey Evanson (Age 55)
Chief Commercial Officer
Comp: $451.17k
Ms. Alicia Tozier
Senior Vice President, Marketing & Market Access
Mr. Joel Prieve
Senior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D.
Senior Vice President of Medical Affairs
Dr. Jennifer M. Kissner Ph.D.
Senior Vice President of Clinical Development & Regulatory Affairs
Mr. Jedd Comiskey
Senior VP - Head of Europe

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OTLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Outlook Therapeutics stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OTLK shares.
View OTLK analyst ratings or view top-rated stocks.
What is Outlook Therapeutics' stock price target for 2024?: 8 brokers have issued twelve-month target prices for Outlook Therapeutics' stock. Their OTLK share price targets range from $20.00 to $100.00. On average, they expect the company's stock price to reach $46.43 in the next year. This suggests a possible upside of 486.2% from the stock's current price.
View analysts price targets for OTLK or view top-rated stocks among Wall Street analysts.
How have OTLK shares performed in 2024?: Outlook Therapeutics' stock was trading at $7.88 on January 1st, 2024. Since then, OTLK shares have increased by 0.5% and is now trading at $7.92.
View the best growth stocks for 2024 here.
When is Outlook Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our OTLK earnings forecast.
How were Outlook Therapeutics' earnings last quarter?: Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its quarterly earnings data on Wednesday, December, 22nd. The company reported ($1.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by $0.60.

When did Outlook Therapeutics' stock split?: Outlook Therapeutics's stock reverse split on the morning of Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Outlook Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), KushCo (KSHB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and CNBX Pharmaceuticals (CNBX).
Who are Outlook Therapeutics' major shareholders?: Outlook Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.62%), Rosalind Advisors Inc. (2.40%), BNP Paribas Financial Markets (0.03%) and American International Group Inc. (0.03%). Insiders that own company stock include C Russell Trenary III, Ghiath M Sukhtian, Jeff Evanson, Kurt J Hilzinger, Terry Dagnon and Yezan Munther Haddadin.
View institutional ownership trends.
How do I buy shares of Outlook Therapeutics?: Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OTLK) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Outlook Therapeutics (OTLK) Stock Price, News & Analysis

Outlook Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows